VectivBio is a technology company.
VectivBio has raised $145.0M across 2 funding rounds.
VectivBio has raised $145.0M in total across 2 funding rounds.
VectivBio AG is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of transformative therapies for severe rare diseases, particularly rare gastrointestinal conditions with high unmet medical needs. Its lead product is apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 (GLP-2), currently in Phase III clinical trials for treating Short Bowel Syndrome with intestinal failure (SBS-IF). VectivBio serves patients with rare diseases and aims to provide best-in-class treatments that address fundamental molecular pathophysiology. The company has demonstrated growth momentum through pipeline expansion, including the acquisition of Comet Therapeutics to broaden its rare disease portfolio[1][3][4].
Founded in 2019 as a spinout from Therachon—a biotech acquired by Pfizer for its achondroplasia program—VectivBio was established by experts with deep experience in rare disease therapeutics. The idea emerged from leveraging prior work on apraglutide and related programs, including assets from GlyPharma Therapeutics acquired by Therachon. Early traction included advancing apraglutide into late-stage clinical trials and expanding its pipeline through strategic acquisitions like Comet Therapeutics, which brought a novel small molecule platform targeting inborn metabolic disorders[1][4].
VectivBio rides the growing trend of precision medicine and rare disease therapeutics, where advances in molecular biology enable targeted treatments for conditions with previously limited options. The timing is favorable due to increasing regulatory support for orphan drugs and rising demand for innovative therapies addressing rare gastrointestinal and metabolic disorders. Market forces such as unmet medical needs, high barriers to entry, and potential for premium pricing support VectivBio’s strategy. By advancing novel treatments, the company contributes to expanding the biotech ecosystem focused on rare diseases and improving patient outcomes globally[1][3][4].
Following its acquisition by Ironwood Pharmaceuticals in 2023 for approximately $1 billion, VectivBio’s lead asset apraglutide is positioned for commercialization under a company with strong gastrointestinal expertise, enhancing its market potential. Future trends shaping its journey include continued innovation in rare disease biology, expansion of pipeline assets through acquisitions or partnerships, and growing patient and payer acceptance of novel therapies. VectivBio’s influence is likely to evolve as a key player in rare GI disease treatment, potentially setting new standards for care and inspiring further biotech innovation in rare conditions[1][6].
VectivBio has raised $145.0M in total across 2 funding rounds.
VectivBio's investors include 5AM Ventures, Deerfield Management, OrbiMed, Versant Ventures.
VectivBio has raised $145.0M across 2 funding rounds. Most recently, it raised $110.0M Venture Round in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $110.0M Venture Round | 5AM Ventures, Deerfield Management, OrbiMed, Versant Ventures | |
| Jan 1, 2020 | $35.0M Series A | 5AM Ventures, Deerfield Management, OrbiMed, Versant Ventures |